DOI: http://dx.doi.org/10.18203/2349-2902.isj20181607

Evaluation of role of granulocyte macrophage colony stimulating factor (GM-CSF) in treatment of patients with perforation peritonitis: a prospective study

Tapan Singh Chauhan, Chisel Bhatia, Satish Dalal, Nityasha Nara, Tulit Chhabra

Abstract


Background: GM-CSF has been demonstrated to be effective in reducing the incidence of infection in patients who receive myelosuppressive anticancer chemotherapy or patients who are neutropenic and agranulocytic. We study the role of GM-CSF in non-neutropenic patients with Systemic Inflammatory Response Syndrome (SIRS), infections and sepsis with impaired neutrophil function to access the current rationale for administering GM-CSF in addition to standard antibiotic therapy to critically ill patients

Methods: All patients undergoing surgery for peritonitis due to gastrointestinal perforations were included in this study and were divided into two groups alternatively to avoid any bias i.e. Group A 1, 3, 5 etc. and Group B 2, 4, 6 etc. Group A - all patients received GM-CSF along with standard antibiotics. Group B patients received antibiotics only. Course of patient in immediate postoperative period, time to improvement, duration of hospital stay, antibiotic therapy, rate of complications were compared.

Results: Patients in group A had a lower duration of antibiotic therapy and hospital stay. Patients in group A took less time to show clinical improvement compared to patients in Group B. Group A also had a much lower rate of infectious and systemic complications compared to group B.

Conclusions: Results of the present study show that GM-CSF is an important molecule when used as adjunct to antibiotics in cases of abdominal sepsis. Use of this growth factor is associated with less incidence of septic complications and morbidity, a shorter duration of antibiotic therapy and hospital stay without significantly compromising the cost. The results of present study help in identifying its role in non-neutropenic patient groups who are most likely to benefit from its administration.


Keywords


Colony stimulating factors, GM-CSF, Perforation peritonitis, SIRS

Full Text:

PDF

References


Jhobta RS, Attri AK, Kaushik R, Sharma R, Jhobta A. Spectrum of perforation peritonitis in lndia - review of 504 consecutive cases. World J Emerg Surg. 2006;1:26.

Nelson S, Begby GJ. Granulocyte colony-stimulating factor and modulation of inflammatory cells in sepsis. Clin Chest Med. 1996;17(2):319-32.

Licschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony stimulating factor. N Engl J Med. 1992;327(2):99-106.

Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician. 2007;1:1005-12.

Rogy M, Fugger R, Schemper M, Koss G, Schulz F. The value of two distinct prognostic score in patients with peritonitis. The Mannheim Peritonitis Index versus the Apache II score. Chirurg. 1990;67(4):297-300.

Billing A, Frohlich D, Schildberg FW. Prediction of outcome using Mannheim peritonitis index in 2003 patients. Peritonitis study group. Br J Surg. 1994;81(2):209-13.

Suanes C, Salvesan H, Espehang B. A multifactorial analysis of factors related to lethality after treatment of perforated gastroduodenal ulcer. Ann Surg. 1989;209:418-23.

Meller AM, Shah K, Bendix J, Jensen AG, Zimmermann-Nielsen E, Adamsen S. Risk factors in patients surgically treated for peptic ulcer perforation. Scand J Gastroenterol. 2009;44:145-52.

Dorairajan LN, Gupta S, Deo SVS, Chumber S, Sharma L. Peritonitis in India: a decades experience. Tropical Gastroenterol. 1995;16:33-8.

Shinagawa N, Muramoto M, Sakurai S, Fukui T, Hon K, Taniguchi M, et al. A bacteriological study of perforated duodenal ulcer. Jap J Surg. 1991;21:17.

Khanna AK, Mishra MK. Typhoid perforation of the gut. Postgraduate Med J. 1984;60:523.

Noon GP, Beall AC, Jorden GL. Clinical evaluation of peritoneal irrigation with antibiotic solution. Surg. 1967;67:73.

Orozco H, Arch J, Medina-Franco H, Pantoja JP, Gonzalez QH, Vilatoba M, et al. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double blind, placebo-controlled clinical trial. Arch Surg. 2006;141(2):150-3.

Metfcalf D, Robb L, Dunn AR, Mifsud S, Di Rogo L. Role of granulocyte- macrophage colony-stimulating factor and granulocyte colony-stimulating factor in the development of acute neutrophil inflammatory response in mice. Blood.1996;88(10):3755-64.

Pistoia V. Granulocyte-Macrophage colony-stimulating factor (GM-CSF); sources, targets and mechanism of action. Leukemia. 1991;5(1):114-8.

Williams MA, Withington S, Newland AC, Kelsey SM. Monocyte anergy in septic shock is associated with a predilection of apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex-vivo. J Infect Dis. 1998;178(5):1421-33.

Arnold F, O'Brien J, Cherry G. Granulocyte monocyte-colony stimulating factor as an agent for wound healing. A study evaluating the use of local injections of a genetically engineered growth factor in the management of wounds with a poor healing response. J Wound Care. 1995;4(9):400-2.

Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edomonds ME. Randomized placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet. 1997;350:855-9.

Bodey GP, Anaissie E, Vadhan G. Role of granulocyte macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis. 1994;13(2):S18-S22.

Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med. 2002;166(2):138-43.

Bilgin K, Yaramis A, Haspolat K, Tas MA, Gunbey S, Derman O. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatr. 2001;107:36-41.

Dierdorf R, Kreuter U, Jones TC. A role for granulocyte-macrophage colony stimulating factor (GM-CSF) in the treatment of neutropenic patients with pneumonia. Braz J Infect Dis. 1997;1:68-76.

Root RK, Dale DC. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in non-neutropenic patients. J Infect Dis. 1999;179(2):S342-52.